Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia

Haematologica

Volumn 89, Issue 12, 2004, Pages

  Arora, Brijesh ^b   Ho, Ching Liang ^b   Hoyer, James O ^b   Mesa, Ruben A ^b   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

Angiogenesis; Myelofibrosis; Myeloid metaplasia

Indexed keywords

CD34 ANTIGEN;

ADULT; AGE; AGED; ANGIOGENESIS; ANGIOGENIC MYELOID METAPLASIA; ARTICLE; BONE MARROW; BONE MARROW ANGIOGENESIS; BONE MARROW BIOPSY; DENSITY; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEGAKARYOCYTE; MICROVASCULATURE; MICROVESSEL DENSITY; MYELOFIBROSIS; MYELOID METAPLASIA; POLYCYTHEMIA; POSTPOLYCYTHEMIC MYELOID METAPLASIA; POSTTHROMBOCYTHEMIA MYELOID METAPLASIA; SPLEEN; THERAPY; THROMBOCYTHEMIA;

AGE FACTORS; AGED; BONE MARROW; COHORT STUDIES; COMBINED MODALITY THERAPY; CYTOKINES; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOGLOBINS; HUMANS; MALE; MEGAKARYOCYTES; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; NEOVASCULARIZATION, PATHOLOGIC; PROSPECTIVE STUDIES; SPLENECTOMY; THROMBOCYTOSIS;

EID: 19744368882     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342: 1255-65.
2. Cervantes F, Barosi G, Demory JL, Reilly J, Guarnone R, Dupriez B, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 1998;102:684-90.
3. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996;88:1013-8.
4. Kvasnicka HM, Thiele J, Staib P, Schmitt-Graeff A, Griesshammer M, Klose J, et al. Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy. Blood 2004;103:3549-51.
5. Reilly JT. Idiopathic myelofibrosis: pathogenesis, natural history and management. Blood Rev 1997;11:233-42.
6. Mesa RA, Hanson CA, Rajkumar SV, Schroeder G, Tefferi A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000;96:3374-80
7. Barosi G, Ambrosetti A, Finelli C, Grossi A, Leoni P, Liberato NL, et al. The Italian Consensus Conference on diagnostic criteria for myelofibrosis with myeloid metaplasia. Br J Haematol 1999; 104: 730-7.
8. Yoon SY, Li CY, Mesa RA, Tefferi A. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 1999; 106: 682-8.
9. Yoon SY, Tefferi A, Li CY. Cellular distribution of platelet-derived growth factor, transforming growth factor-β, basic fibroblast growth factor, and their receptors in normal bone marrow. Acta Haematol 2000;104:151-7
10. Fox SB. Tumour angiogenesis and prognosis. Histopathology 1997;30:294-301.
11. Weidner N. Tumor angiogenesis - review of current applications in tumor prognostication. Semin Diagn Pathol 1993; 10:302-13.
12. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000;96:2240-5.
13. Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000;6:3111-6.
14. Mesa RA, Hanson CA, Rajkumar SV, Schroeder G, Tefferi A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000; 96:3374-80.
15. Lundberg LG, Lerner R, Sundelin P, Rogers R, Folkman J, Palmblad J. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol 2000; 157:15-9.
16. Di Raimondo F, Azzaro MP, Palumbo GA, Bagnato S, Stagno F, Giustolisi GM, et al. Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemi 2001;15:976-80.
17. Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clinical Cancer Res 2002;8:2210-6.
18. Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci PF, et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999;81:1398-401.
19. Thiele J, Rompcik V, Wagner S, Fischer R. Vascular architecture and collagen type IV in primary myelofibrosis and polycythaemia vera: an immunomorphometric study on trephine biopsies of the bone marrow. Br J Haematol 1992;80:227-34.
20. Thiele J, Kvasnicka HM, Fischer R, Diehl V. Clinicopathological impact of the interaction between megakaryocytes and myeloid stroma in chronic myeloproliferative disorders: a concise update. Leuk Lymphoma 1997;24:463-81.
21. Kvasnicka HM, Thiele J, Staib P, Engels K, Kriener S, Schmitt-Graeff A. Therapy-related changes of angiogenesis in Philadelphia chromosome positive chronic myelogenous leukemia Pathologe 2004;25:127-34.
22. Di Raimondo F, Palumbo GA, Molica S, Giustolisi R. Angiogenesis in chronic myeloproliferative diseases. Acta Haematol 2001;106:177-83.
23. Gasparini G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2001;2:733-40.
24. Musolino C, Calabro L, Bellomo G, Martello F, Loteta B, Pezzano C, et al. Soluble angiogenic factors: implications for chronic myeloproliferative disorders. Am J Hematol 2002;69:159-63.
25. Murphy P, Ahmed N, Hassan HT. Increased serum levels of vascular endothelial growth factor correlate with splenomegaly in polycythemia vera. Leuk Res 2002;26:1007-10.
26. Wolf BC, Banks PM, Mann RB, Neiman RS. Splenic hematopoiesis in polycythemia vera. A morphologic and immunohistologic study. Am J Clin Pathol 1988; 89:69-75.
27. Mesa RA, Rajkumar SV, Hanson CA, Schroeder GS, Tefferi A. Evaluation and clinical correlations of microvessel density in myelofibrosis with myeloid metaplasia. Blood 1999;94:115a-15a.